Shares of Amylin Pharmaceuticals (NASDAQ:AMLN) are trading 13.5% higher to $23.00 premarket Monday after the U.S. Food and Drug Administration asked for more information related to existing manufacturing processes, risk management and labeling for the Type 2 diabetes drug Byetta.
Though, the FDA didn't request new tests or information related to quality-control violations identified in a December inspection of the plant where the drug is made.
Link to this comment:
All Comments (0)